A review of genetic counseling for charcot marie tooth disease (CMT)

Journal of Genetic Counseling

Volumn 22, Issue 4, 2013, Pages 422-436

  Siskind, Carly E ^a   Panchal, Seema ^b,c   Smith, Corrine O ^d   Feely, Shawna M E ^e   Dalton, Joline C ^f   Schindler, Alice B ^g   Krajewski, Karen M ^h  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF IOWA HEALTH CARE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

Author keywords

Charcot Marie Tooth disease; CMT; Ethical concerns; Genetic counseling; Genetic subtypes; Hereditary motor and sensory neuropathy; Psychosocial concerns

Indexed keywords

GENETIC COUNSELING; GENETICS; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; POINT MUTATION; REVIEW; CHARCOT-MARIE-TOOTH DISEASE;

CHARCOT-MARIE-TOOTH DISEASE; GENETIC COUNSELING; HUMANS; POINT MUTATION;

EID: 84879928803     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-013-9584-4     Document Type: Review

References (106)

1. 2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-28 September 1997, Naarden, The Netherlands. (1998). Neuromuscul Disord, 8(6), 426-431.
2. Andersson, P. B.; Yuen, E.; Parko, K.; So, Y. T. (2000). Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology, 54(1), 40-44.
3. Antonellis, A.; Ellsworth, R. E.; Sambuughin, N.; Puls, I.; Abel, A.; Lee-Lin, S. Q.; et al. (2003). Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. American Journal of Human Genetics, 72(5), 1293-1299.
4. Arnold, A.; McEntagart, M.; Younger, D. S. (2005). Psychosocial issues that face patients with Charcot-Marie-Tooth disease: the role of genetic counseling. Journal of Genetic Counseling, 14(4), 307-318.
5. Auer-Grumbach, M.; De Jonghe, P.; Wagner, K.; Verhoeven, K.; Hartung, H. P.; Timmerman, V. (2000). Phenotype-genotype correlations in a CMT2B family with refined 3q13-q22 locus. Neurology, 55(10), 1552-1557.
6. Azzedine, H.; Bolino, A.; Taieb, T.; Birouk, N.; Di Duca, M.; Bouhouche, A.; et al. (2003). Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. American Journal of Human Genetics, 72(5), 1141-1153.
7. Azzedine, H.; Ravise, N.; Verny, C.; Gabreels-Festen, A.; Lammens, M.; Grid, D.; et al. (2006). Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology, 67(4), 602-606.
8. Baxter, R. V.; Ben Othmane, K.; Rochelle, J. M.; Stajich, J. E.; Hulette, C.; Dew-Knight, S.; et al. (2002). Ganglioside-induced differentiation- associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nature Genetics, 30(1), 21-22.
9. Bergoffen, J.; Scherer, S. S.; Wang, S.; Scott, M. O.; Bone, L. J.; Paul, D. L.; et al. (1993). Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science, 262(5142), 2039-2042.
10. Bienfait, H. M.; Verhamme, C.; van Schaik, I. N.; Koelman, J. H.; de Visser, B. W.; de Haan, R. J.; et al. (2006). Comparison of CMT1A and CMT2: similarities and differences. Journal of Neurology, 253(12), 1572-1580.
11. Bienfait, H. M.; Baas, F.; Koelman, J. H.; de Haan, R. J.; van Engelen, B. G.; Gabreels-Festen, A. A.; et al. (2007). Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology, 68(20), 1658-1667.
12. Boerkoel, C. F.; Takashima, H.; Stankiewicz, P.; Garcia, C. A.; Leber, S. M.; Rhee-Morris, L.; et al. (2001). Periaxin mutations cause recessive Dejerine-Sottas neuropathy. American Journal of Human Genetics, 68(2), 325-333.
13. Boerkoel, C. F.; Takashima, H.; Garcia, C. A.; Olney, R. K.; Johnson, J.; Berry, K.; et al. (2002). Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Annals of Neurology, 51(2), 190-201.
14. Boerkoel, C. F.; Takashima, H.; Nakagawa, M.; Izumo, S.; Armstrong, D.; Butler, I.; et al. (2003). CMT4A: identification of a Hispanic GDAP1 founder mutation. Annals of Neurology, 53(3), 400-405.
15. Bolino, A.; Lonie, L. J.; Zimmer, M.; Boerkoel, C. F.; Takashima, H.; Monaco, A. P.; et al. (2001). Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy. Neurogenetics, 3(2), 107-109.
16. Bras, J.; Guerreiro, R.; Hardy, J. (2012). Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nature Reviews Neuroscience, 13(7), 453-464.
17. Buschbacher, R. M.; Prahlow, N. D. (2006). Manual of nerve conduction studies manual of nerve conduction studies (2nd ed.). New York: Demos Medical Publishing, LLC.
18. Chance, P. F.; Alderson, M. K.; Leppig, K. A.; Lensch, M. W.; Matsunami, N.; Smith, B.; et al. (1993). DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell, 72(1), 143-151.
19. Charcot, J. M.; Marie, P. (1886). Sur une forme particuliere d'atrophie musculaire progressive, souvent familiale, debutante par les pieds et les jambes et atteignant plus tard les mains. Rev Med Parie, 6, 97-138.
20. Chen, D. H.; Sul, Y.; Weiss, M.; Hillel, A.; Lipe, H.; Wolff, J.; et al. (2010). CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology, 75(22), 1968-1975.
21. Chung, K. W.; Kim, S. B.; Park, K. D.; Choi, K. G.; Lee, J. H.; Eun, H. W.; et al. (2006). Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain, 129(Pt 8), 2103-2118.
22. Chung, K. W.; Kim, S. B.; Cho, S. Y.; Hwang, S. J.; Park, S. W.; Kang, S. H.; et al. (2008). Distal hereditary motor neuropathy in Korean patients with a small heat shock protein 27 mutation. Experimental & Molecular Medicine, 40(3), 304-312.
23. Claramunt, R.; Pedrola, L.; Sevilla, T.; Lopez de Munain, A.; Berciano, J.; Cuesta, A.; et al. (2005). Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. Journal of Medical Genetics, 42(4), 358-365.
24. Colomer, J.; Gooding, R.; Angelicheva, D.; King, R. H.; Guillen-Navarro, E.; Parman, Y.; et al. (2006). Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2. Neuromuscular Disorders, 16(7), 449-453.
25. Crimella, C.; Tonelli, A.; Airoldi, G.; Baschirotto, C.; D'Angelo, M. G.; Bonato, S.; et al. (2010). The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2 K. Journal of Medical Genetics, 47(10), 712-716.
26. De Jonghe, P.; Timmerman, V.; FitzPatrick, D.; Spoelders, P.; Martin, J. J.; Van Broeckhoven, C. (1997). Mutilating neuropathic ulcerations in a chromosome 3q13-q22 linked Charcot-Marie-Tooth disease type 2B family. Journal of Neurology, Neurosurgery, and Psychiatry, 62(6), 570-573.
27. Deng, H. X.; Klein, C. J.; Yan, J.; Shi, Y.; Wu, Y.; Fecto, F.; et al. (2010). Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nature Genetics, 42(2), 165-169.
28. Dyck, P. J.; Lambert, E. H. (1968). Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Archives of Neurology, 18(6), 603-618.
29. Dyck, P. J.; Litchy, W. J.; Minnerath, S.; Bird, T. D.; Chance, P. F.; Schaid, D. J.; et al. (1994). Hereditary motor and sensory neuropathy with diaphragm and vocal cord paresis. Annals of Neurology, 35(5), 608-615.
30. England, J. D.; Gronseth, G. S.; Franklin, G.; Carter, G. T.; Kinsella, L. J.; Cohen, J. A.; et al. (2009). Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology, 72(2), 185-192.
31. Evgrafov, O. V.; Mersiyanova, I.; Irobi, J.; Van Den Bosch, L.; Dierick, I.; Leung, C. L.; et al. (2004). Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nature Genetics, 36(6), 602-606.
32. Feely, S. M.; Laura, M.; Siskind, C. E.; Sottile, S.; Davis, M.; Gibbons, V. S.; et al. (2011). MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology, 76(20), 1690-1696.
33. Gabreels-Festen, A. A.; Bolhuis, P. A.; Hoogendijk, J. E.; Valentijn, L. J.; Eshuis, E. J.; Gabreels, F. J. (1995). Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathologica, 90(6), 645-649.
34. Georgiou, D. M.; Zidar, J.; Korosec, M.; Middleton, L. T.; Kyriakides, T.; Christodoulou, K. (2002). A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics, 4(2), 93-96.
35. Gooding, R.; Colomer, J.; King, R.; Angelicheva, D.; Marns, L.; Parman, Y.; et al. (2005). A novel Gypsy founder mutation, p.Arg1109X in the CMT4C gene, causes variable peripheral neuropathy phenotypes. Journal of Medical Genetics, 42(12), e69.
36. Greenfield, S.; Brostoff, S.; Eylar, E. H.; Morell, P. (1973). Protein composition of myelin of the peripheral nervous system. Journal of Neurochemistry, 20(4), 1207-1216.
37. Guilbot, A.; Williams, A.; Ravise, N.; Verny, C.; Brice, A.; Sherman, D. L.; et al. (2001). A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Human Molecular Genetics, 10(4), 415-421.
38. Harding, A. E.; Thomas, P. K. (1980). The clinical features of hereditary motor and sensory neuropathy types I and II. Brain, 103(2), 259-280.
39. Hayasaka, K.; Himoro, M.; Sato, W.; Takada, G.; Uyemura, K.; Shimizu, N.; et al. (1993). Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nature Genetics, 5(1), 31-34.
40. Houlden, H.; Laura, M.; Wavrant-De Vrieze, F.; Blake, J.; Wood, N.; Reilly, M. M. (2008). Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology, 71(21), 1660-1668.
41. Jordanova, A.; De Jonghe, P.; Boerkoel, C. F.; Takashima, H.; De Vriendt, E.; Ceuterick, C.; et al. (2003). Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain, 126(Pt 3), 590-597.
42. Kabzinska, D.; Drac, H.; Sherman, D. L.; Kostera-Pruszczyk, A.; Brophy, P. J.; Kochanski, A.; et al. (2006). Charcot-Marie-Tooth type 4 F disease caused by S399fsx410 mutation in the PRX gene. Neurology, 66(5), 745-747.
43. Kamholz, J.; Menichella, D.; Jani, A.; Garbern, J.; Lewis, R. A.; Krajewski, K. M.; et al. (2000). Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain, 123(Pt 2), 222-233.
44. Klein, C. J.; Cunningham, J. M.; Atkinson, E. J.; Schaid, D. J.; Hebbring, S. J.; Anderson, S. A.; et al. (2003). The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology, 60(7), 1151-1156.
45. Krajewski, K. M.; Lewis, R. A.; Fuerst, D. R.; Turansky, C.; Hinderer, S. R.; Garbern, J.; et al. (2000). Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain, 123(Pt 7), 1516-1527.
46. Krakow, D.; Vriens, J.; Camacho, N.; Luong, P.; Deixler, H.; Funari, T. L.; et al. (2009). Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia. American Journal of Human Genetics, 84(3), 307-315.
47. Kwon, J. M.; Elliott, J. L.; Yee, W. C.; Ivanovich, J.; Scavarda, N. J.; Moolsintong, P. J.; et al. (1995). Assignment of a second Charcot-Marie-Tooth type II locus to chromosome 3q. American Journal of Human Genetics, 57(4), 853-858.
48. Landoure, G.; Zdebik, A. A.; Martinez, T. L.; Burnett, B. G.; Stanescu, H. C.; Inada, H.; et al. (2010). Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nature Genetics, 42(2), 170-174.
49. Lassuthova, P.; Mazanec, R.; Vondracek, P.; Siskova, D.; Haberlova, J.; Sabova, J.; et al. (2011). High frequency of SH3TC2 mutations in Czech HMSN I patients. Clin Genet.
50. Latour, P.; Gonnaud, P. M.; Ollagnon, E.; Chan, V.; Perelman, S.; Stojkovic, T.; et al. (2006). SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. Journal of the Peripheral Nervous System, 11(2), 148-155.
51. Lawson, V. H.; Graham, B. V.; Flanigan, K. M. (2005). Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology, 65(2), 197-204.
52. Lenssen, P. P.; Gabreels-Festen, A. A.; Valentijn, L. J.; Jongen, P. J.; van Beersum, S. E.; van Engelen, B. G.; et al. (1998). Hereditary neuropathy with liability to pressure palsies. Phenotypic differences between patients with the common deletion and a PMP22 frame shift mutation. Brain, 121(Pt 8), 1451-1458.
53. Lewis, R. A.; McDermott, M. P.; Herrmann, D.; Hoke, A.; Siskind, C.; Feely, S. M.; et al. (In press). High Dose Ascorbic Acid Treatment in CMT-1A: Resuls of a Randomized Double-Masked Controlled Trial. JAMA Neurology.
54. Li, J.; Krajewski, K.; Shy, M. E.; Lewis, R. A. (2002). Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology, 58(12), 1769-1773.
55. Lupski, J. R.; de Oca-Luna, R. M.; Slaugenhaupt, S.; Pentao, L.; Guzzetta, V.; Trask, B. J.; et al. (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell, 66(2), 219-232.
56. Marchesi, C.; Milani, M.; Morbin, M.; Cesani, M.; Lauria, G.; Scaioli, V.; et al. (2010). Four novel cases of periaxin-related neuropathy and review of the literature. Neurology, 75(20), 1830-1838.
57. Marques, W.; Jr.; Freitas, M. R.; Nascimento, O. J.; Oliveira, A. B.; Calia, L.; Melo, A.; et al. (2005). 17p duplicated Charcot-Marie-Tooth 1A: characteristics of a new population. Journal of Neurology, 252(8), 972-979.
58. Mersiyanova, I. V.; Perepelov, A. V.; Polyakov, A. V.; Sitnikov, V. F.; Dadali, E. L.; Oparin, R. B.; et al. (2000). A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. American Journal of Human Genetics, 67(1), 37-46.
59. Micallef, J.; Attarian, S.; Dubourg, O.; Gonnaud, P. M.; Hogrel, J. Y.; Stojkovic, T.; et al. (2009). Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, 8(12), 1103-1110.
60. Misu, K.; Yoshihara, T.; Shikama, Y.; Awaki, E.; Yamamoto, M.; Hattori, N.; et al. (2000). An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). Journal of Neurology, Neurosurgery, and Psychiatry, 69(6), 806-811.
61. Murphy, S. M.; Laura, M.; Fawcett, K.; Pandraud, A.; Liu, Y. T.; Davidson, G. L.; et al. (2012). Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. Journal of Neurology, Neurosurgery, and Psychiatry, 83(7), 706-710.
62. Murphy, S. M.; Ovens, R.; Polke, J.; Siskind, C. E.; Laura, M.; Bull, K.; et al. (2012). X inactivation in females with X-linked Charcot-Marie-Tooth disease. Neuromuscul Disord.
63. Nelis, E.; Erdem, S.; Van Den Bergh, P. Y.; Belpaire-Dethiou, M. C.; Ceuterick, C.; Van Gerwen, V.; et al. (2002). Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy. Neurology, 59(12), 1865-1872.
64. Neusch, C.; Senderek, J.; Eggermann, T.; Elolff, E.; Bahr, M.; Schneider-Gold, C. (2007). Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A). European Journal of Neurology, 14(5), 575-577.
65. Pareyson, D.; Reilly, M. M.; Schenone, A.; Fabrizi, G. M.; Cavallaro, T.; Santoro, L.; et al. (2011). Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, 10(4), 320-328.
66. Parman, Y.; Battaloglu, E.; Baris, I.; Bilir, B.; Poyraz, M.; Bissar-Tadmouri, N.; et al. (2004). Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain, 127(Pt 11), 2540-2550.
67. Pfeiffer, G.; Wicklein, E. M.; Ratusinski, T.; Schmitt, L.; Kunze, K. (2001). Disability and quality of life in Charcot-Marie-Tooth disease type 1. Journal of Neurology, Neurosurgery, and Psychiatry, 70(4), 548-550.
68. Pitceathly, R. D.; Murphy, S. M.; Cottenie, E.; Chalasani, A.; Sweeney, M. G.; Woodward, C.; et al. (2012). Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology, 79(11), 1145-1154.
69. Rock, M. J.; Prenen, J.; Funari, V. A.; Funari, T. L.; Merriman, B.; Nelson, S. F.; et al. (2008). Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nature Genetics, 40(8), 999-1003.
70. Russo, M.; Laura, M.; Polke, J. M.; Davis, M. B.; Blake, J.; Brandner, S.; et al. (2011). Variable phenotypes are associated with PMP22 missense mutations. Neuromuscular Disorders, 21(2), 106-114.
71. Saifi, G. M.; Szigeti, K.; Wiszniewski, W.; Shy, M. E.; Krajewski, K.; Hausmanowa-Petrusewicz, I.; et al. (2005). SIMPLE mutations in Charcot-Marie-Tooth disease and the potential role of its protein product in protein degradation. Human Mutation, 25(4), 372-383.
72. Santoro, L.; Manganelli, F.; Di Maio, L.; Barbieri, F.; Carella, M.; D'Adamo, P.; et al. (2002). Charcot-Marie-Tooth disease type 2C: a distinct genetic entity. Clinical and molecular characterization of the first European family. Neuromuscular Disorders, 12(4), 399-404.
73. Saporta, A. S.; Sottile, S. L.; Miller, L. J.; Feely, S. M.; Siskind, C. E.; Shy, M. E. (2011). Charcot-marie-tooth disease subtypes and genetic testing strategies. Annals of Neurology, 69(1), 22-33.
74. Senderek, J.; Bergmann, C.; Ramaekers, V. T.; Nelis, E.; Bernert, G.; Makowski, A.; et al. (2003). Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy. Brain, 126(Pt 3), 642-649.
75. Senderek, J.; Bergmann, C.; Stendel, C.; Kirfel, J.; Verpoorten, N.; De Jonghe, P.; et al. (2003). Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. American Journal of Human Genetics, 73(5), 1106-1119.
76. Senderek, J.; Bergmann, C.; Weber, S.; Ketelsen, U. P.; Schorle, H.; Rudnik-Schoneborn, S.; et al. (2003). Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Human Molecular Genetics, 12(3), 349-356.
77. Sevilla, T.; Cuesta, A.; Chumillas, M. J.; Mayordomo, F.; Pedrola, L.; Palau, F.; et al. (2003). Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain, 126(Pt 9), 2023-2033.
78. Sheth, S.; Francies, K.; Siskind, C. E.; Feely, S. M.; Lewis, R. A.; Shy, M. E. (2008). Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. Journal of the Peripheral Nervous System, 13(4), 299-304.
79. Shy, M. E.; Siskind, C.; Swan, E. R.; Krajewski, K. M.; Doherty, T.; Fuerst, D. R.; et al. (2007). CMT1X phenotypes represent loss of GJB1 gene function. Neurology, 68(11), 849-855.
80. Siskind, C.; Feely, S. M.; Bernes, S.; Shy, M. E.; Garbern, J. Y. (2009). Persistent CNS dysfunction in a boy with CMT1X. Journal of Neurological Sciences, 279(1-2), 109-113.
81. Siskind, C. E.; Murphy, S. M.; Ovens, R.; Polke, J.; Reilly, M. M.; Shy, M. E. (2011). Phenotype expression in women with CMT1X. Journal of the Peripheral Nervous System, 16(2), 102-107.
82. Sivakumar, K.; Kyriakides, T.; Puls, I.; Nicholson, G. A.; Funalot, B.; Antonellis, A.; et al. (2005). Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain, 128(Pt 10), 2304-2314.
83. Sivera, R.; Espinos, C.; Vilchez, J. J.; Mas, F.; Martinez-Rubio, D.; Chumillas, M. J.; et al. (2010). Phenotypical features of the p.R120W mutation in the GDAP1 gene causing autosomal dominant Charcot-Marie-Tooth disease. Journal of the Peripheral Nervous System, 15(4), 334-344.
84. Skre, H. (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clinical Genetics, 6(2), 98-118.
85. Solla, P.; Vannelli, A.; Bolino, A.; Marrosu, G.; Coviello, S.; Murru, M. R.; et al. (2010). Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry, 81(9), 958-962.
86. Street, V. A.; Bennett, C. L.; Goldy, J. D.; Shirk, A. J.; Kleopa, K. A.; Tempel, B. L.; et al. (2003). Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology, 60(1), 22-26.
87. Sulonen, A. M.; Ellonen, P.; Almusa, H.; Lepisto, M.; Eldfors, S.; Hannula, S.; et al. (2011). Comparison of solution-based exome capture methods for next generation sequencing. Genome Biology, 12(9), R94.
88. Szigeti, K.; Wiszniewski, W.; Saifi, G. M.; Sherman, D. L.; Sule, N.; Adesina, A. M.; et al. (2007). Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations. Neurogenetics, 8(4), 257-262.
89. Tang, B. S.; Luo, W.; Xia, K.; Xiao, J. F.; Jiang, H.; Shen, L.; et al. (2004). A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Human Genetics, 114(6), 527-533.
90. Tang, B. S.; Zhao, G. H.; Luo, W.; Xia, K.; Cai, F.; Pan, Q.; et al. (2005). Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2 L. Human Genetics, 116(3), 222-224.
91. Thomas, P. K.; Marques, W.; Jr.; Davis, M. B.; Sweeney, M. G.; King, R. H.; Bradley, J. L.; et al. (1997). The phenotypic manifestations of chromosome 17p11.2 duplication. Brain, 120(Pt 3), 465-478.
92. Thompson, R.; Drew, C. J.; Thomas, R. H. (2012). Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. Advances in Protein Chemistry and Structural Biology, 89, 27-63.
93. Tooth, H. H. (1886). The peroneal type of progressive muscular atrophy. London: Lewis.
94. Tyson, J.; Ellis, D.; Fairbrother, U.; King, R. H.; Muntoni, F.; Jacobs, J.; et al. (1997). Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain, 120(Pt 1), 47-63.
95. Vandenberghe, N.; Upadhyaya, M.; Gatignol, A.; Boutrand, L.; Boucherat, M.; Chazot, G.; et al. (2002). Frequency of mutations in the early growth response 2 gene associated with peripheral demyelinating neuropathies. Journal of Medical Genetics, 39(12), e81.
96. Verhamme, C.; van Schaik, I. N.; Koelman, J. H.; de Haan, R. J.; de Visser, M. (2009). The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain, 132(Pt 12), 3252-3262.
97. Verhoeven, K.; De Jonghe, P.; Coen, K.; Verpoorten, N.; Auer-Grumbach, M.; Kwon, J. M.; et al. (2003). Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. American Journal of Human Genetics, 72(3), 722-727.
98. Verhoeven, K.; Claeys, K. G.; Zuchner, S.; Schroder, J. M.; Weis, J.; Ceuterick, C.; et al. (2006). MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain, 129(Pt 8), 2093-2102.
99. Verny, C.; Ravise, N.; Leutenegger, A. L.; Pouplard, F.; Dubourg, O.; Tardieu, S.; et al. (2004). Coincidence of two genetic forms of Charcot-Marie-Tooth disease in a single family. Neurology, 63(8), 1527-1529.
100. Warner, L. E.; Mancias, P.; Butler, I. J.; McDonald, C. M.; Keppen, L.; Koob, K. G.; et al. (1998). Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nature Genetics, 18(4), 382-384.
101. Warner, L. E.; Garcia, C. A.; Lupski, J. R. (1999). Hereditary peripheral neuropathies: clinical forms, genetics, and molecular mechanisms. Annual Review of Medicine, 50, 263-275.
102. Weimer, L. H.; Podwall, D. (2006). Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. Journal of Neurological Sciences, 242(1-2), 47-54.
103. Yoshihara, T.; Kanda, F.; Yamamoto, M.; Ishihara, H.; Misu, K.; Hattori, N.; et al. (2001). A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot-Marie-Tooth disease type 1. Journal of Neurological Sciences, 184(2), 149-153.
104. Yoshihara, T.; Yamamoto, M.; Hattori, N.; Misu, K.; Mori, K.; Koike, H.; et al. (2002). Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. Journal of the Peripheral Nervous System, 7(4), 221-224.
105. Zuchner, S.; Vance, J. M. (2006). Molecular genetics of autosomal-dominant axonal Charcot-Marie-Tooth disease. Neuromolecular Medicine, 8(1-2), 63-74.
106. Zuchner, S.; Mersiyanova, I. V.; Muglia, M.; Bissar-Tadmouri, N.; Rochelle, J.; Dadali, E. L.; et al. (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genetics, 36(5), 449-451.